Literature DB >> 25081580

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Martin A Katzman, Pierre Bleau, Pierre Blier, Pratap Chokka, Kevin Kjernisted, Michael Van Ameringen, Martin M Antony, Stéphane Bouchard, Alain Brunet, Martine Flament, Sophie Grigoriadis, Sandra Mendlowitz, Kieron O'Connor, Kiran Rabheru, Peggy M A Richter, Melisa Robichaud, John R Walker.   

Abstract

BACKGROUND: Anxiety and related disorders are among the most common mental disorders, with lifetime prevalence reportedly as high as 31%. Unfortunately, anxiety disorders are under-diagnosed and under-treated.
METHODS: These guidelines were developed by Canadian experts in anxiety and related disorders through a consensus process. Data on the epidemiology, diagnosis, and treatment (psychological and pharmacological) were obtained through MEDLINE, PsycINFO, and manual searches (1980-2012). Treatment strategies were rated on strength of evidence, and a clinical recommendation for each intervention was made, based on global impression of efficacy, effectiveness, and side effects, using a modified version of the periodic health examination guidelines.
RESULTS: These guidelines are presented in 10 sections, including an introduction, principles of diagnosis and management, six sections (Sections 3 through 8) on the specific anxiety-related disorders (panic disorder, agoraphobia, specific phobia, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, and posttraumatic stress disorder), and two additional sections on special populations (children/adolescents, pregnant/lactating women, and the elderly) and clinical issues in patients with comorbid conditions.
CONCLUSIONS: Anxiety and related disorders are very common in clinical practice, and frequently comorbid with other psychiatric and medical conditions. Optimal management requires a good understanding of the efficacy and side effect profiles of pharmacological and psychological treatments.

Entities:  

Mesh:

Year:  2014        PMID: 25081580      PMCID: PMC4120194          DOI: 10.1186/1471-244X-14-S1-S1

Source DB:  PubMed          Journal:  BMC Psychiatry        ISSN: 1471-244X            Impact factor:   3.630


  1415 in total

1.  Bupropion-SR in treatment of social phobia.

Authors:  N P Emmanuel; O Brawman-Mintzer; W A Morton; S W Book; M R Johnson; J P Lorberbaum; J C Ballenger; R B Lydiard
Journal:  Depress Anxiety       Date:  2000       Impact factor: 6.505

2.  Cognitive-behavioral treatment of anxiety disorders in children: long-term (6-year) follow-up.

Authors:  P M Barrett; A L Duffy; M R Dadds; R M Rapee
Journal:  J Consult Clin Psychol       Date:  2001-02

3.  Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn.

Authors:  Susan E Andrade; Heather McPhillips; David Loren; Marsha A Raebel; Kimberly Lane; James Livingston; Denise M Boudreau; David H Smith; Robert L Davis; Mary E Willy; Richard Platt
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-03       Impact factor: 2.890

4.  Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.

Authors:  Ali Ghaleiha; Neda Entezari; Amirhossein Modabbernia; Babak Najand; Neda Askari; Mina Tabrizi; Mandana Ashrafi; Reza Hajiaghaee; Shahin Akhondzadeh
Journal:  J Psychiatr Res       Date:  2012-10-09       Impact factor: 4.791

5.  Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients.

Authors:  Nienke C C Vulink; Damiaan Denys; Sjoerd B A H A Fluitman; Jantien C M Meinardi; Herman G M Westenberg
Journal:  J Clin Psychiatry       Date:  2009-06-02       Impact factor: 4.384

6.  The efficacy of videotape feedback for enhancing the effects of exposure-based treatment for social anxiety disorder: a controlled investigation.

Authors:  Jasper A J Smits; Mark B Powers; Rachel Buxkamper; Michael J Telch
Journal:  Behav Res Ther       Date:  2006-02-20

7.  Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.

Authors:  Jamie D Feusner; Lauren Kerwin; Sanjaya Saxena; Alexander Bystritsky
Journal:  Psychopharmacol Bull       Date:  2009

8.  A pilot randomized trial of metacognitive therapy vs applied relaxation in the treatment of adults with generalized anxiety disorder.

Authors:  Adrian Wells; Mary Welford; Paul King; Costas Papageorgiou; Julie Wisely; Elizabeth Mendel
Journal:  Behav Res Ther       Date:  2010-01-04

9.  Symptom presentation and classroom functioning in a nonclinical sample of children with social phobia.

Authors:  Gail A Bernstein; Debra H Bernat; Andrew A Davis; Ann E Layne
Journal:  Depress Anxiety       Date:  2008       Impact factor: 6.505

10.  Treatment of specific phobia in older adults.

Authors:  Nancy A Pachana; Rana M Woodward; Gerard J A Byrne
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

View more
  147 in total

1.  Topiramate augmentation in a patient with obsessive-compulsive disorder.

Authors:  Michael Van Ameringen; Beth Patterson
Journal:  J Psychiatry Neurosci       Date:  2015-09       Impact factor: 6.186

2.  Association between suicide death and concordance with benzodiazepine treatment guidelines for anxiety and sleep disorders.

Authors:  Jennifer M Boggs; Richard C Lindrooth; Catherine Battaglia; Arne Beck; Debra P Ritzwoller; Brian K Ahmedani; Rebecca C Rossom; Frances L Lynch; Christine Y Lu; Beth E Waitzfelder; Ashli A Owen-Smith; Gregory E Simon; Heather D Anderson
Journal:  Gen Hosp Psychiatry       Date:  2019-11-17       Impact factor: 3.238

3.  Changes in temporal attention inhibition following prolonged exposure and sertraline in the treatment of PTSD.

Authors:  Aileen Echiverri-Cohen; Lori A Zoellner; Robert Gallop; Norah Feeny; Jeffrey Jaeger; Michele Bedard-Gilligan
Journal:  J Consult Clin Psychol       Date:  2016-02-22

4.  Impulsive aggressive obsessions following cerebellar strokes: a case study.

Authors:  Arnaud Tessier; Charlotte Cosin; Willy Mayo; Micha Pfeuty; David Misdrahi; Igor Sibon
Journal:  J Neurol       Date:  2015-06-06       Impact factor: 4.849

5.  N-Acetylcysteine augmentation in refractory obsessive–compulsive disorder

Authors:  Sreenivasa Bhaskara
Journal:  J Psychiatry Neurosci       Date:  2019-05-01       Impact factor: 6.186

6.  Sex and gender considerations in Canadian clinical practice guidelines: a systematic review.

Authors:  Cara Tannenbaum; Barbara Clow; Margaret Haworth-Brockman; Patrice Voss
Journal:  CMAJ Open       Date:  2017-02-10

7.  Alcohol use disorder and depression: proposed rewording of Choosing Wisely recommendation.

Authors:  Robert L Tanguay; Wiplove Lamba; Ronald Fraser; Phillip Mills; Ataa Azarbar; Nady El-Guebaly
Journal:  CMAJ       Date:  2017-03-20       Impact factor: 8.262

8.  Refractory social anxiety disorder.

Authors:  Michael Van Ameringen; Beth Patterson
Journal:  J Psychiatry Neurosci       Date:  2017-01       Impact factor: 6.186

9.  Contemporary Psychiatry, Psychoanalysis, and Psychotherapy.

Authors:  Paula Ravitz
Journal:  Can J Psychiatry       Date:  2017-05       Impact factor: 4.356

Review 10.  Can Long-Term Pharmacotherapy Prevent Relapses in Generalized Anxiety Disorder? A Systematic Review.

Authors:  Marina Dyskant Mochcovitch; Rafael Christophe da Rocha Freire; Rafael Ferreira Garcia; Antonio Egidio Nardi
Journal:  Clin Drug Investig       Date:  2017-08       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.